Denosumab

Denosumab: The Injection You Cannot Simply Stop — Rebound, Jaw, Calcium

Denosumab is an antibody that strongly slows down bone loss and, in osteoporosis, is injected under the skin every six months. Unlike bisphosphonates, it is not stored in the bone — if the effect ends without follow-on treatment, bone breakdown can return with a vengeance and trigger spinal fractures. On top of that come two rare but important risks: calcium levels that drop too low, and osteonecrosis of the jaw.

See more detail

Never miss your next denosumab appointment again

Six months is long enough to forget an appointment — the brite app reminds you in good time. Free.

Add injection date

Contents

  1. At a Glance: Technical Data Sheet
  2. How it works: a brake that only holds as long as the injection
  3. Dosing: telling the osteoporosis dose from the cancer dose
  4. Everyday use: the six-month rhythm
  5. Side effects: calcium, infections, bones
  6. Stopping: why denosumab never simply ends
  7. Osteonecrosis of the jaw: teeth before and during treatment
  8. Interactions
  9. Monitoring: what counts before every injection
  10. Denosumab compared with bisphosphonates and others
  11. Special situations: kidneys, pregnancy, cancer, cortisone
  12. Denosumab experiences: what patients really ask
  13. FAQ: Common questions about denosumab

1. At a Glance: Technical Data Sheet

PropertyDetails
Active ingredientDenosumab (fully human monoclonal antibody)
ATC codeM05BX04
Drug classAntiresorptive; RANKL inhibitor (slows down the cells that break down bone)
Dosage formsPre-filled syringe for injection under the skin; osteoporosis product (e.g. Prolia) and higher-dose cancer product (e.g. Xgeva), each now also available as a biosimilar
Half-lifeAround 26 days on average according to the SmPC; the bone-protecting effect wears off around six months after the injection
Maximum daily doseNo daily dose: in osteoporosis, 60 mg every six months according to the SmPC; with bone metastases, 120 mg every four weeks. The prescription is set by the practice
Onset of effectMarkers of bone breakdown fall within days; bone density rises over months and years; fewer spinal fractures as early as the first year of treatment
Prescription statusPrescription-only medicine
Notable featureNot stored in the bone: once the effect ends, there is a risk of excessive bone breakdown (rebound) with spinal fractures — so never stop or postpone it without a plan
Table scrolls to the right

2. How it works: a brake that only holds as long as the injection

Bone is constantly being remodelled. Bone-resorbing cells (osteoclasts) remove old bone, and bone-forming cells (osteoblasts) replace it. In osteoporosis, breakdown predominates — the bone becomes porous and breaks more easily, typically in the vertebrae, hip and wrist.¹,²,³

For osteoclasts to form and work, they need a signal: a messenger substance called RANKL. Denosumab is an antibody that intercepts RANKL. Without this signal, hardly any new osteoclasts are formed, and the existing ones work less. Bone breakdown drops markedly within a few days, and bone density then rises steadily over years.¹

This principle gives rise to strengths and risks in equal measure:

  • A strong, even effect: in trials, denosumab lowered the risk of spinal fractures, hip fractures and other fractures. An increase in bone density was still seen even after many years of treatment.¹,²
  • Independent of the kidneys: as an antibody, denosumab is not excreted via the kidneys. That makes it an option when bisphosphonates are ruled out because of weak kidneys.
  • No depot effect: bisphosphonates such as alendronic acid are stored in the bone and keep working for a long time after they are stopped. Denosumab does not. Once it is broken down, the brake is suddenly released — and the pent-up remodelling overshoots. This is the core of this article (section 6).
  • Less calcium released from bone: when bone breakdown suddenly stops, less calcium is released from the bone. This can lower the calcium level in the blood, especially with weak kidneys or vitamin D deficiency.
Important context. Denosumab is an effective osteoporosis medicine — but one that demands a strict rhythm. If you decide on it, you are also deciding on a plan for how things will continue at some point. That question belongs at the beginning of treatment, not at its end.²

3. Dosing: telling the osteoporosis dose from the cancer dose

The following information describes the approach according to the SmPC. It is not a dosing instruction — the product, dose and interval are set by the treating practice.¹

Area of useUsual regimen according to the SmPCNotable feature
Osteoporosis after the menopause and in men at increased risk of fracture60 mg every six months under the skinLong-term treatment with planned follow-on
Bone loss due to hormone ablation in prostate cancer60 mg every six monthsSame product as for osteoporosis
Bone loss due to long-term cortisone60 mg every six monthsSame product as for osteoporosis
Bone metastases from solid tumours, multiple myeloma, giant cell tumour of bone120 mg every four weeksA different product with a much higher total dose — osteonecrosis of the jaw and calcium deficiency are more common here
Table scrolls to the right
  • Calcium and vitamin D are part of it: according to the SmPC, everyone being treated must have an adequate supply of calcium and vitamin D — usually through diet plus a supplement. Any existing calcium deficiency must be corrected before the first injection.
  • No adjustment for kidneys or age: the dose stays the same; with severely weakened kidneys, however, the risk of a drop in calcium rises markedly (section 5).
  • Never two denosumab products at the same time: if you receive the cancer product, you do not also get the osteoporosis product — it is the same active ingredient.
  • Biosimilars: biological follow-on products are now available. They are considered equivalent. When switching products, the only important thing is that the six-month rhythm does not slip.

4. Everyday use: the six-month rhythm

Two injections a year sound like the most convenient osteoporosis treatment of all. That is exactly where the risk lies: an appointment that only comes round every six months is easily lost when you change doctor, go into hospital or move house.

  1. Fix the appointment straight away. The date of the next injection follows from the last one: six months later. Ask for the appointment at the time of the injection and enter it with a reminder.
  2. Avoid delays. After about six months, the effect wears off. Professional societies advise not to exceed the appointment by more than a few weeks if possible.⁴
  3. Make up a missed injection straight away. According to the SmPC, a missed dose is given as soon as possible; after that, the rhythm is based on the new date.¹
  4. Before every injection: keep an eye on calcium. The SmPC recommends checking the calcium level before every dose and, if you are at increased risk, additionally in the first weeks after the first injection.
  5. Calcium and vitamin D every day. The supplement is not an optional extra but part of the treatment. Calcium supplements have their own spacing rules with other tablets — for example with levothyroxine or certain antibiotics.
  6. Injecting at home? After training, patients or relatives can inject it themselves; the usual sites are the thigh, abdomen or upper arm. The pre-filled syringe is stored in the fridge; according to the SmPC, it may be kept at room temperature (up to 25 °C) once for up to 30 days. More on this under storing medications correctly.
The patient card belongs in your wallet. Denosumab comes with a reminder card with information about osteonecrosis of the jaw. Show it at every dental practice — and note the date of your last injection on it or in your medication plan. This one piece of information decides what happens next in many situations.

Six months go by faster than you think

A reminder before your next appointment, calcium and vitamin D in your daily plan — all in one place.

Set up a reminder

5. Side effects: calcium, infections, bones

On the osteoporosis schedule, most people tolerate denosumab well. Common side effects are pain in the arms and legs as well as muscle and bone pain, plus urinary and respiratory tract infections.¹ The following points are rarer, but deserve particular attention.

Calcium levels that are too low (hypocalcaemia)

Denosumab can lower the calcium level in the blood. With healthy kidneys and a good vitamin D supply, this is rarely pronounced. With severely weakened kidneys or on dialysis, however, severe and sometimes life-threatening cases have been described; in 2024, the US Food and Drug Administration added a particularly prominent warning (boxed warning) about this.¹,⁵

Warning signs of calcium deficiency. Tingling around the mouth or in the fingers and toes, muscle twitching, painful cramps in the hands, feet or calves, palpitations or confusion — especially in the days and weeks after an injection. If you notice these signs, contact your practice without delay; with a seizure, severe muscle cramps, shortness of breath or impaired consciousness, call 112 (emergency number in Germany) immediately.

Skin infections

Occasionally, bacterial skin infections (cellulitis) occur that may require hospital treatment. A red, warm, painful and spreading area of skin — often on the lower leg — possibly with fever, should be seen by a doctor quickly.¹

Atypical thigh bone fractures

Rarely, long-term antiresorptive treatment leads to unusual fractures of the shaft of the thigh bone under minor strain. They often announce themselves over weeks with dull pain in the thigh, hip or groin. New pain of this kind should be investigated before it turns into a fracture.¹

Other side effects

  • Skin: rash and eczema have been described.
  • Bowel: occasionally diverticulitis (inflammation of pouches in the bowel wall).
  • Eyes: cataracts were observed more often in men receiving hormone ablation for prostate cancer.
  • Jaw and ear canal: rare bone necrosis in the jaw — see section 7 — and very rarely in the external ear canal.
  • Allergy: rarely hypersensitivity reactions. With some pre-filled syringes, the needle cap contains natural rubber — important if you have a latex allergy.

How to record and report your observations is explained in the guide side effects of medications.

6. Stopping: why denosumab never simply ends

This is the most important section of this article. With many medicines, stopping means that the effect ends and the original state returns. With denosumab, more happens. During treatment, hardly any new osteoclasts are formed, but their precursor cells accumulate. When the effect ends, they all become active at the same time. Bone breakdown then rises for a while above the level before treatment — a rebound.¹,⁴

The consequences according to the SmPC and professional societies:

  • The bone density gained is lost, typically within one to two years of the last injection.
  • Several spinal fractures can occur in quick succession (multiple vertebral fractures) — even in people who had no fracture before. The risk begins a few months after the injection that was due but not given.
  • The SmPC therefore provides that treatment is not interrupted without a medical review and that, when it is stopped, a switch to another antiresorptive treatment is considered.¹
Do not stop or postpone it on your own. Not because of a good bone density result, nor because of dental treatment, a house move or a trip. Sudden, new back pain a few months after a missed injection can point to spinal fractures and should be checked by a doctor promptly.

What a planned exit looks like

If denosumab is to be ended — because bone density has risen sufficiently, side effects occur or your life situation changes — the DVO guideline and European professional societies recommend follow-on treatment, usually with a bisphosphonate.²,⁴

  1. Raise it early. The question "What happens after denosumab?" should be on the table at least one appointment before the planned last injection.
  2. Decide on the follow-on medicine. The usual options are an infusion of zoledronic acid or taking alendronic acid. Which medicine, when exactly and for how long is decided by the practice — after long-term denosumab treatment, often over a longer period.
  3. Get the timing right. The follow-on medicine is usually started around the date on which the next denosumab injection would have been due — not months later.
  4. Monitor. Bone turnover markers in the blood and bone density show whether the rebound is being sufficiently slowed. After several years of denosumab treatment, a single dose does not always achieve this; the treatment is then adjusted.

To be honest: a perfect exit is not guaranteed after long-term treatment. Some of the bone density gained can be lost despite follow-on treatment. That is not an argument against denosumab — but it is very much an argument for taking the exit as seriously as the start. General rules on stopping are explained in the guide stopping medications.

7. Osteonecrosis of the jaw: teeth before and during treatment

In osteonecrosis of the jaw, a piece of jawbone dies and becomes exposed, often after a tooth has been pulled. The wound does not heal, hurts or becomes inflamed. According to the SmPC, this side effect is rare on the osteoporosis schedule, but common with the high-dose cancer product.¹

The risk rises with certain factors: tooth extraction and other procedures on the jawbone, inflamed gums and periodontitis, poorly fitting dentures, smoking, cancer and chemotherapy, cortisone and a long duration of treatment.¹

  • Before starting treatment — if there are risk factors, according to the SmPC a dental examination, with any necessary treatment done before the first injection if possible.
  • During treatment — careful oral hygiene, regular check-ups and professional teeth cleaning, and having dentures fitted properly.
  • At every dental visit — mention denosumab and the date of the last injection. Tips on preparing are given in the guide medications before the dentist.
If a tooth has to be pulled. With bisphosphonates, a treatment break is sometimes discussed. With denosumab, skipping an injection is not a simple solution because of the rebound. How the procedure is timed in relation to the injection is agreed jointly by the dental practice or oral surgery and the prescribing practice. Get in touch if you have a loose tooth, pain, swelling, exposed bone or a wound in your mouth that does not heal. More on medicines and oral health in the guide medications and dental health.

8. Interactions

As an antibody, denosumab is not broken down by the liver enzymes that cause most interactions with tablets. What matters most are combinations that amplify the same risks: low calcium, osteonecrosis of the jaw and infections.¹

CombinationConsequenceWhat to do
Another denosumab product (cancer and osteoporosis product)Double dose of the same active ingredientNever combine; inform all prescribing practices
Cortisone, e.g. prednisoloneHigher risk of osteonecrosis of the jaw and infections; cortisone itself weakens the boneTake oral hygiene especially seriously; see the cortisone guide
Chemotherapy, angiogenesis inhibitorsMarkedly higher risk of osteonecrosis of the jawHave your dental status checked before starting
ImmunosuppressantsPossibly higher risk of serious infectionsHave signs of infection checked early
Calcium-lowering medicines, e.g. cinacalcet, loop diuretics such as furosemideCalcium levels can fall furtherMonitor calcium more closely
Calcium supplementsA necessary addition, but spacing from some tablets is neededPlan gaps from levothyroxine, iron and some antibiotics
AlcoholNo direct interaction; harms the bone and raises the risk of fallsRestraint; see medications and alcohol
Table scrolls to the right

The real interaction is an organisational one. Denosumab does not appear on many medication plans at all, because it is not taken daily but injected twice a year at the practice. The dental practice, hospital or oncology team often only find out about it if you mention it yourself. So enter the injection with its date in your plan and check new prescriptions with the interaction check of the brite app. Which medicines weaken the bone in their own right is shown in the guide medications and osteoporosis risk.

9. Monitoring: what counts before every injection

CheckWhenWhy
Calcium in the bloodBefore every injection; if at risk, additionally in the first weeks after the first doseTo detect hypocalcaemia early
Kidney function (eGFR)Before starting and over timeSeverely weakened kidneys markedly increase the calcium risk
Vitamin DBefore starting, and over time if neededA deficiency intensifies the drop in calcium
Dental statusBefore starting and regularlyTo prevent osteonecrosis of the jaw
Bone density (DXA scan)As determined by the practice, usually at intervals of yearsTreatment success and planning the exit
Bone turnover markersAbove all after switching to a follow-on medicineTo check whether the rebound is being slowed
Table scrolls to the right

It is worth knowing your own calcium and vitamin D values. How to make sense of lab results is explained in understanding blood values.

10. Denosumab compared with bisphosphonates and others

According to the DVO guideline, the choice of osteoporosis medicine depends above all on the individual fracture risk, accompanying conditions and tolerability.² The foundation remains the same for all of them: calcium, vitamin D, exercise and fall prevention.³

Active ingredient (class)Principle and administrationKidneysAfter stopping
DenosumabSlows breakdown; injection every six monthsNo adjustment, but calcium risk with severe impairmentRebound — follow-on treatment needed
Bisphosphonates, e.g. alendronic acid, zoledronic acidSlow breakdown; tablet weekly or infusion yearlyUsually unsuitable with severely weakened kidneysKeep working; treatment breaks are possible
Bone-building medicines (e.g. teriparatide, romosozumab)Promote bone formation; daily or monthly injection, for a limited timeDepends on the active ingredientAlso need antiresorptive follow-on treatment
Table scrolls to the right

Typical reasons for denosumab are intolerance of bisphosphonate tablets, weak kidneys that rule out bisphosphonates, or difficulties with the strict rules for taking the tablets. Conversely, it speaks against denosumab if the regular injection every six months cannot be reliably guaranteed — in that case, a bisphosphonate with a lasting after-effect may be the more robust choice. The treatment decision lies with the treating practice.

11. Special situations: kidneys, pregnancy, cancer, cortisone

Severely weakened kidneys and dialysis

This is the most important special situation. The dose stays the same, but the risk of severe hypocalcaemia is markedly increased, especially as chronic kidney disease often also involves a disorder of bone and mineral metabolism that can resemble osteoporosis. This disorder is investigated before starting, and calcium is monitored particularly closely.¹,⁵

Pregnancy and breastfeeding

According to the SmPC, denosumab is not recommended in pregnancy; women of childbearing age should not become pregnant during treatment and for at least five months afterwards.¹ As osteoporosis treatments are mainly used after the menopause, this affects few people — but it is relevant for glucocorticoid-induced osteoporosis in younger women. Independent advice is available from Embryotox.⁶

Cancer treatment

For bone metastases, the higher-dose product is used. Osteonecrosis of the jaw and hypocalcaemia are markedly more common here, so the dental status before starting is all the more important. A rebound is also possible when this treatment is ended — the treatment team plans for that.

Cortisone and hormone ablation

If you take cortisone long term or receive hormone ablation therapy for prostate cancer, you lose bone faster. Denosumab is licensed for both situations. The basic rules — rhythm, calcium, jaw, planned exit — apply in exactly the same way.

Children and adolescents

The osteoporosis product is not intended for children and adolescents. In young people, a dangerous rise in calcium levels has also been described after stopping.¹

12. Denosumab experiences: what patients really ask

"I missed my injection appointment — I'm now three weeks overdue. Is that bad?"

It is no reason to panic, but it is a reason to act — today, not after your holiday. According to the SmPC, a missed injection is made up as soon as possible. A few weeks' delay is usually still not critical; the longer the gap, the closer you get to the phase in which the rebound begins. Call the practice, say explicitly "denosumab, overdue" and ask for a prompt appointment. After that, the six-month rhythm is based on the new date. And then: set up a reminder that warns you a few weeks in advance.

"My bone density is good now. Can I stop?"

Perhaps — but not just like that. Improved bone density is a success of the treatment, not proof that the bone will stay stable without it. With denosumab, every ending comes with a follow-on plan, usually with a bisphosphonate. So do not ask "Can I stop?", but "What would a safe exit look like for me — and is now the right time?". Sometimes the answer is to carry on for now; sometimes now is a good time for the planned switch.

"My dentist wants to pull a tooth. Do I have to skip the injection?"

Not on your own initiative. Skipping a denosumab injection hardly protects the jaw, but it does risk the rebound in the spine. Tell the dental practice that you receive denosumab and when your last injection was, and ask them to coordinate with your prescribing practice. If the risk is higher, an oral surgery practice often takes on the procedure with special precautions. Important afterwards: if the wound does not heal or bone is exposed, get in touch immediately.

"After the injection, I have tingling around my mouth. Is that normal?"

No, you should take it seriously. Tingling around the mouth or in the fingers, muscle twitching and cramps can be signs of calcium levels that are too low. Contact the practice on the same day so that the calcium in your blood can be measured. A seizure, severe muscle cramps, a racing heart or shortness of breath are an emergency for 112. If you have kidney disease or your vitamin D level was low, raise the subject before the next injection.

Does every practice know you are on denosumab?

A digital medication plan also shows the injection that is only due twice a year — including the date.

Create a plan

FAQ: Common questions about denosumab

Denosumab is not stored in the bone. If the effect ends without follow-on treatment, bone breakdown temporarily rises above its original level, the bone density gained is lost and several spinal fractures can occur. That is why the exit is planned, usually with a bisphosphonate.
According to the SmPC, the missed injection is made up as soon as possible, and the six-month rhythm then runs from the new date. A delay of a few weeks is usually not yet critical, but longer gaps increase the risk of a rebound. So contact your practice without delay.
At the osteoporosis dose, osteonecrosis of the jaw is rare according to the SmPC, but it is common at the high dose used for bone metastases. The risk rises with tooth extraction, periodontitis, poorly fitting dentures, smoking, cortisone and cancer treatment. Good oral hygiene and regular dental visits lower it.
According to the SmPC, everyone being treated must have an adequate supply of calcium and vitamin D, usually through diet and a supplement. Any existing calcium deficiency is corrected before the first injection. How much you need is set by the practice based on your values.
Typical signs are tingling around the mouth or in the fingers and toes, muscle twitching, cramps, palpitations or confusion, especially in the weeks after an injection. The calcium level should then be measured promptly. With a seizure, severe cramps or shortness of breath: call 112 immediately.
Yes, the dose does not need to be adjusted, because the antibody is not excreted via the kidneys. With severely weakened kidneys or on dialysis, however, the risk of a dangerous drop in calcium is markedly increased. That is why bone metabolism is investigated beforehand and calcium is monitored particularly closely.
Both contain denosumab. The osteoporosis product is injected every six months at a lower dose, the cancer product for bone metastases every four weeks at a higher dose. Osteonecrosis of the jaw and calcium deficiency are more common at the high dose. The two must not be used at the same time; biosimilars are now available for both.
There is no fixed maximum duration; treatment is reviewed regularly on the basis of fracture risk, bone density and tolerability. What matters is that an end is always planned with follow-on treatment. The decision is made by the treating practice together with you.

Sources

  1. Summaries of Product Characteristics (SmPCs) for denosumab (Prolia, 60 mg; Xgeva, 120 mg; EMA product information, current version; biosimilars accordingly). ema.europa.eu
  2. S3 guideline on the prevention, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged 50 and over (Dachverband Osteologie, DVO, the umbrella association of German-speaking osteology societies, 2023) — German source. awmf.org
  3. Gesundheitsinformation.de (IQWiG): Osteoporosis — treatment with medicines and prevention. Accessed 2026 — German source. gesundheitsinformation.de
  4. Tsourdi E. et al.: Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. Journal of Clinical Endocrinology & Metabolism 2021. academic.oup.com
  5. U.S. Food and Drug Administration: Drug Safety Communication — Boxed Warning on severe hypocalcaemia with Prolia (denosumab) in advanced chronic kidney disease (2024). fda.gov
  6. Embryotox, Charité — German pharmacovigilance and advisory centre for embryonic toxicology: medicines in pregnancy and breastfeeding. Accessed 2026. embryotox.de

Protect your bones, keep the rhythm — with brite

Injection dates, calcium and vitamin D, lab values and interactions in one place. Free.

Create medication plan
brite App
Medical disclaimer: This article is for general information and does not replace medical advice, diagnosis or treatment. Do not stop denosumab on your own and do not postpone an injection without checking first — without planned follow-on treatment, there is a risk of rapid bone loss and spinal fractures. If you have tingling around the mouth, muscle cramps or a seizure, a wound in your mouth that does not heal or new back pain after a missed injection, seek medical help promptly or, in an emergency, call 112 (emergency number in Germany). The choice of medicine and the dose are always set individually by the treating practice. Last updated: September 2026.